Influenza Clinical Trial
Official title:
Strategies to Vaccinate All Children for Influenza in a Practice Setting
Beginning with the 2009-2010 season, influenza vaccine is universally recommended for children age 6 months to 18 years old, placing extra burden on health care providers across the U.S. The focus of this study is to develop new strategies and implement existing evidence-based strategies to enhance influenza immunization in these children. The intervention will involve collaboration from different types of primary care providers, the Colorado Immunization Information System (CIIS), public health departments and visiting nursing services (VNA). It will be designed and implemented by those involved with delivery with a focus on sustainability after the completion of the study. Parental input will be gathered during the planning year through focus groups to assist in developing the intervention. Qualitative assessments and examination of processes during the first year of implementation will guide modifications during the second implementation year in order to assure sustainability. Primary outcome measures in the intervention and control groups: 1) increase in the rate of receipt of ≥1 influenza vaccine during the post-intervention year compared to the pre-intervention year among children 6 mo.-18 yr. and 2) increase in the rate of children 6 mo.-18 yr. who were fully immunized (received all required influenza injections) during the season. 3) measure outcomes by age group (6 mo.-5 yr., 6-8 yr., 9-12 yr., 13-18 yr.) and types of clinical sites (urban Peds, urban FM, rural FM)
Specific Aim 1: Within each of three types of clinical sites (urban pediatric, urban family
medicine, and rural family medicine) recruit a group of similar practices (Year 1) 1a.
Randomize practices within each type of clinical site to either the intervention or the
control group
1b. Establish private-public collaborations for influenza vaccination delivery between
county public health departments, visiting nursing associations and each of the intervention
practices within the three clinical site types
Specific Aim 2: Conduct focus groups among parents of children seen at intervention
practices, to assess attitudes and perceived barriers to possible practice-based and
collaborative strategies to promote influenza vaccination (Year 1)
Specific Aim 3: Develop (Year 1) and implement (Years 2 and 3) a plan for comprehensive and
collaborative delivery of influenza vaccine at intervention practices 3a. Develop
practice-based intervention strategies focusing primarily on immunization of high-risk
patients 3b. Develop private-public collaborative interventions between the intervention
practices, their county public health department and visiting nursing associations focusing
primarily on immunization of school-aged children 3c. Implement (Years 2 and 3) both
practice-based and private-public collaborative strategies in the intervention practices
while monitoring only in the control practices
Specific Aim 4: Conduct a group-randomized trial to evaluate and compare the effectiveness
of the comprehensive delivery model in improving influenza vaccination coverage for children
6 months to 18 years in three different types of clinical sites (urban pediatric, urban
family medicine, and rural family medicine).
4a. Evaluate effectiveness of the comprehensive delivery model at each of the three types of
clinical sites
1. Compare the following primary outcome measures in the intervention and control groups:
1) increase in the rate of receipt of ≥1 influenza vaccine during the post-intervention
year compared to the pre-intervention year among children 6 months to 18 years and 2)
increase in the rate of children 6 months to 18 years who were fully immunized
(received all required influenza injections) during the season.
2. Compare the following secondary outcome measures: 1) increase in the rate of receipt of
≥1 influenza vaccine during the post-intervention year compared to the pre-intervention
year among high-risk children and 2) increase in the rate of high-risk children who
were fully immunized during the season.
3. Evaluate sustainability of the comprehensive delivery model on the above outcome
measures
4b. Compare the effectiveness of the comprehensive delivery model in three different types
of clinical sites (urban pediatric private practice, urban family medicine private practice,
and rural family medicine private practice)
Specific Aim 5: Evaluate the process of implementation of the comprehensive delivery model
for influenza delivery in each of the three types of sites.
5a. Assess process measures relevant to implementation of practice-based interventions and
compare by type of clinical site 5b. Assess process measures relevant to implementation of
private-public collaborative interventions and compare by type of clinical site 5c. Using
key informant interviews, assess perceptions regarding facilitators and barriers to
private-public collaborative delivery, alternative methods and means of improving the
process among practice providers, administrators and among participating public health and
visiting nurse personnel
Specific Aim 6: In two urban pediatric intervention practices and one rural family medicine
practice, conduct surveys examining parental attitudes about methods of influenza delivery
and their experience with their practice's participation in a comprehensive and
collaborative private-public model for influenza delivery
Major Hypotheses:
SA4. Hypothesis 1. Effectiveness on receipt of ≥1 influenza vaccine: The increase in the
likelihood of receiving ≥1 influenza vaccine during the post-intervention year compared to
the pre-intervention year among children 6 months to 18 years will be greater for children
in intervention practices than in control practices.
SA4. Hypothesis 2 Effectiveness - fully immunized: The increase in the likelihood of
receiving all necessary influenza vaccines during the post-intervention year compared to the
pre-intervention year among children 6 months to 18 years will be greater for children in
intervention practices than in control practices.
SA4. Hypothesis 3. Effectiveness by age strata: The increase in the likelihood of receiving
≥1 influenza vaccine during the post-intervention year compared to the pre-intervention year
among children in each of the following age strata will be greater in intervention than in
control practices: 1) 6 months through 5 years; 2) 6 through 8 years; 3) 9 through 12 years;
4) 13 through 18 years.
SA4. Hypothesis 4. Effectiveness in high-risk children: The increase in the likelihood of
receiving of ≥1 influenza vaccine during the post-intervention year compared to the
pre-intervention year among high-risk children 6 months to 18 years will be greater for
high-risk children in intervention practices than in control practices.
SA4. Hypothesis 5. Sustainability: The increase in the likelihood of receiving ≥1 influenza
vaccine during the second post-intervention year compared to the pre-intervention year among
children 6 months to 18 years will be greater for children in intervention practices than in
control practices. (Sustainability will also be evaluated for other outcomes above.)
SA4. Hypothesis 6. Differential effectiveness by clinical site type: The increase in the
likelihood of receiving of ≥1 influenza vaccine during the post-intervention year compared
to the pre-intervention year among children 6 months to 18 years for intervention vs.
controls will differ by clinical site type
;
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT05523089 -
The Effectiveness of CD388 to Prevent Flu in an Influenza Challenge Model in Healthy Adults
|
Phase 2 | |
| Completed |
NCT05009251 -
Using Explainable AI Risk Predictions to Nudge Influenza Vaccine Uptake
|
N/A | |
| Completed |
NCT03282240 -
Safety and Immunogenicity of High-Dose Quadrivalent Influenza Vaccine in Participants ≥65 Years in the US
|
Phase 3 | |
| Completed |
NCT00968539 -
Study to Evaluate the Immunogenicity & Safety of an Investigational Influenza Vaccine (H1N1) in Adults
|
Phase 3 | |
| Completed |
NCT00971425 -
Evaluation of the Immune Response and the Safety of a Pandemic Influenza Candidate Vaccine (H1N1)
|
Phase 3 | |
| Completed |
NCT00968526 -
Study to Evaluate Immunogenicity and Safety of an Investigational Influenza Vaccine (H1N1) in Adults
|
Phase 3 | |
| Completed |
NCT05525494 -
Patient Portal Flu Vaccine Reminders (5)
|
N/A | |
| Completed |
NCT04074928 -
Safety and Immunogenicity Study of QIVc in Healthy Pediatric Subjects
|
Phase 3 | |
| Completed |
NCT04695717 -
This Study Was Conducted to Evaluate the Safety and Immunogenicity of IVACFLU-S Produced in Children From 6 Months to Under 18 Years Old and the Elderly Over 60 Years Old in Vietnam
|
Phase 3 | |
| Completed |
NCT05012163 -
Lottery Incentive Nudges to Increase Influenza Vaccinations
|
N/A | |
| Completed |
NCT03888989 -
Response to Influenza Vaccine During Pregnancy
|
Phase 1 | |
| Completed |
NCT04109222 -
Collection of Serum Samples From Children and Older Adults Receiving the 2019-2020 Formulations of Fluzone® Quadrivalent and Fluzone® High-Dose Influenza Vaccines, Respectively
|
Phase 4 | |
| Completed |
NCT02587221 -
Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Influenza Vaccine Compared to Non-influenza Vaccine Comparator in Adults ≥ 65 Years of Age
|
Phase 3 | |
| Completed |
NCT03453801 -
The Role of CD4+ Memory Phenotype, Memory, and Effector T Cells in Vaccination and Infection
|
Phase 1 | |
| Completed |
NCT01440387 -
A Study of Immunogenicity and Safety of GSK Biologicals' Influenza Vaccine FLU-Q-QIV in Adults Aged 18 Years and Older
|
Phase 3 | |
| Terminated |
NCT01195779 -
Trial to Evaluate Safety and Immunogenicity of GSK Biologicals' Influenza Vaccine GSK2584786A in Healthy Children
|
Phase 2 | |
| Completed |
NCT03321968 -
Lot-to-lot Consistency of a Plant-Derived Quadrivalent Virus-Like Particles Influenza Vaccine in Healthy Adults
|
Phase 3 | |
| Completed |
NCT00972517 -
Study to Evaluate the Immunogenicity and Safety of an Investigational Influenza Vaccine (H1N1) in Children
|
Phase 3 | |
| Completed |
NCT04570904 -
Broadening Our Understanding of Early Versus Late Influenza Vaccine Effectiveness
|
||
| Recruiting |
NCT03331991 -
Prevention of Influenza and Other Wintertime Respiratory Viruses Among Healthcare Professionals in Israel
|
N/A |